Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 17, 2011European Journal of Heart FailureOpen Access

Thrombopoietin Protects Against Doxorubicin-Induced Cardiomyopathy, Improves Cardiac Function, and Reversely Alters Specific Signalling Networks

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does thrombopoietin improve cardiac function in rat models of doxorubicin-induced cardiomyopathy?

Population

Rat models of acute and chronic doxorubicin (DOX)-induced heart damage

Comparison

Thrombopoietin vs Doxorubicin treatment alone (implied)

Design

Preclinical

Follow-up

5 days (acute model) and 11 weeks (chronic model)

Authors

KCKathy Yuen Yee ChanPXPing XiangLZLigang Zhou

Discussion

Loading...

Member takes

Overview

Findings remain preclinical; leaves open TPO translation to human doxorubicin cardiomyopathy.

Structured PICO

Does thrombopoietin improve cardiac function in rat models of doxorubicin-induced cardiomyopathy?

P
Population
Rat models of acute and chronic doxorubicin (DOX)-induced heart damage
I
Intervention
Thrombopoietin (TPO) (four doses in acute model; three doses weekly for 6 weeks in chronic model)
C
Comparator
Doxorubicin treatment alone (implied)
O
Outcome
Fractional shortening, cardiac output, and morphologic parameterssurrogate

Thrombopoietin promotes cardiac protection from acute and chronic doxorubicin insults in rat models, improving cardiac function and morphology.

Cite This Study

Chan et al. (2011) studied this question.

synapsesocial.com/papers/6a81ff1b2ac899ae0206ec9bhttps://doi.org/10.1093/eurjhf/hfr001
View Full Paper
Ask AI
Bookmark
Share